CD79B.md
... ...
@@ -12,7 +12,7 @@ This has clinical and therapeutic implications as it may contribute sensitivity
12 12
In an inducible mouse model of MYD88-driven DLBCL, CD79B mutations did not accelerate lymphomagenesis but demonstrated an increased sensitivity to pharmacological BTK inhibition.[@flumannInducibleCd79bMutation2024]
13 13
In a retrospective analysis, younger patients with MCD DLBCL that were treated with ibrutinib had significantly better outcomes.[@wilsonEffectIbrutinibRCHOP2021b]
14 14
The most common hotspot mutation in CD79B is at the tyrosine residue 196 (Y196).
15
-This and other common mutations primarily occur in the immunoreceptor tyrosine-based activation motif (ITAM) domain and prevent the negative regulatory feedback provided by Lyn kinase thereby enhancing BCR signaling.[@kimCD79BMYD88Mutations2014]
15
+This and other common mutations primarily occur in the immunoreceptor tyrosine-based activation motif (ITAM) domain and prevent the negative regulatory feedback provided by Lyn kinase thereby enhancing BCR signaling.[@kimCD79BMYD88Mutations2014; @davisChronicActiveBcellreceptor2010]
16 16
17 17
18 18
## History
... ...
@@ -36,7 +36,7 @@ timeline
36 36
37 37
|Entity|Tier|Description |
38 38
|:------:|:----:|--------------------------------------|
39
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|
39
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-EE |high-confidence DLBCL gene with functional evidence[@davisChronicActiveBcellreceptor2010] [@morinFrequentMutationHistonemodifying2011]|
40 40
|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established|
41 41
|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
42 42